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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To evaluate the clinical effectiveness and acceptability of family therapy as a treatment to enhance communication or coping for
individuals with ASD and their family members. If possible, we will also seek to establish the economic costs associated with family
therapy for this clinical population.
B A C K G R O U N D
Description of the condition
Autism spectrum disorders (ASD) are a cluster of childhood onset
neurodevelopmental conditions characterised by qualitative im-
pairments in communication, reciprocal social interaction, and
restricted and repetitive interests and behaviours (WHO 1992).
There is substantial heterogeneity in the ASD symptom profile
and clinical presentation; hence, diagnosis is often not made until
late adolescence or adulthood (NICE 2012). Once thought to be
fairly rare, current prevalence estimates indicate that ASD is rel-
atively common, affecting at least 1% of the population (Brugha
2011).
The degree of impairment resulting from core ASD characteris-
tics varies widely. Educational attainments are often poorer for
younger people with ASD in comparison to typically developing
peers (Levy 2011). Similarly, the adult ASD population experi-
ences significant difficulty with gaining and sustaining meaning-
ful employment (Howlin 2013; Mavranezouli 2014). A lack of
peer and intimate relationships are frequently the norm (White
2009a), leading to diminished social opportunities beyond those
that stem from the family network, social isolation, and loneli-
ness. Daily living and self sufficiency skills can also be impeded,
and individuals with ASD often depend on ongoing support from
family members well into adulthood (Gray 2014; Magiati 2014).
ASD are commonly associated with learning disability and high
rates of psychiatric comorbidity (Hofvander 2009; Joshi 2013;
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Simonoff 2008), including anxiety disorders (Van Steensel 2011;
White 2009b), depression (Ghaziuddin 2002), attention deficit
hyperactivity disorder traits (Taylor 2013), and more general
“emotional and behavioural problems” (Maskey 2013). Comor-
bidities further compound difficulties across multiple domains of
functioning and exacerbate reliance on family members as well as
carer stress and burden (Cadman 2012).
The experiences and needs of family members of individuals with
ASD have garnered increasing attention in recent years. Findings
from epidemiological and genetic studies indicate that ASD is a
highly heritable condition (Hallmayer 2011; Lichtenstein 2010;
Lundström 2010). Also, studies have found that parents of people
with ASD can present with higher levels of stress, distress, fatigue,
anxiety, and depression symptoms than those reported for par-
ents of typically developing or other clinical populations (Cadman
2012; Firth 2013; Giallo 2013; Hoefman 2014). Additionally, re-
search findings suggest that carers can experience concerns about
their parental efficacy and coping (Karst 2012). There has been
some, albeit limited, research about siblings of individuals with
ASD.Tentative study findings suggest that some siblingsmay expe-
rience slightly elevated levels of “behavioural problems” compared
to non-clinical populations (Hastings 2014), or features of anxi-
ety (Shivers 2013). Sibling adjustment and relationships may be
affected by the severity of ASD and associated symptoms (Petalas
2012). Siblings may also be expected to take on more household
duties (for example, chores), or more responsibility (for example,
informal caregiving) compared to the individual with ASD, al-
though this is not a consistent finding across studies (Meirsschaut
2011).
Description of the intervention
Family therapy can be defined as a formal psychotherapeutic inter-
vention that seeks to understand and enhance relationships, com-
munication, and functioning betweenmembers of a family (Dallos
2010).While there are several types of family therapy, they are pre-
dominantly underpinned by systemic theories and share central
tenets (Hayes 1991). First, it is proposed that various problems,
such asmental health functioning or the development andmainte-
nance of interpersonal relationships, are contextually bound (that
is they are likely to be predisposed and perpetuated by the context
and system(s) within which they occur, rather than solely being
attributed to the individual themselves) (Dallos 2010). Second, it
is suggested that societal and cultural norms, values, and expecta-
tions influence and shape familial beliefs and behaviours both col-
lectively (that is the intergenerational family unit) and individu-
ally, and that problems are best understood and addressed in terms
of these influences. Third, it is hypothesised that the family unit
and the relationships between family members are dynamic (that
is that the reactions and responses of one person affect those of
others in the system, in a bi-directional fashion, linearly and longi-
tudinally). Fourth, families are said to develop ways of coping with
periods of change and transition (for example, births, marriages,
and bereavements), and illness or adversity, in order to maintain
stability as a unit (Goldenberg 2012).Oftentimes these patterns of
coping are adaptive and shared between all familymembers, yet on
occasion, individuals (within the family) may adopt distinct cop-
ing styles leading to communication and relationship difficulties.
Finally, it is considered that there are commonalities in the ways
that family members use language and narratives to converse and
make sense of their own and others’ experiences, but also subtle
differences, which in turn may lead to or exacerbate ambiguity,
misinterpretation, or disagreements.
Family therapists use a range of interventions (Dallos 2010), in-
cluding psychoeducation; development of genograms to map out
cultural, resilience, or other familial patterns (Butler 2008); narra-
tive techniques (for example, to explore language, meanings, and
attributions) (Carr 1998); and the use of particular questioning
styles (for example, circular and reflexive questions to enhance the
breadth and depth of discussion) (Hayes 1991). In clinical prac-
tice, individuals presenting for family therapy may be part of the
same family or part of the wider friendship group. Individuals are
encouraged to decide for themselves who can and will engage in
treatment, and the configuration of those attendingmay vary from
session to session. The duration of therapy can be several weeks to
several months. Choices about the number of sessions to offer are
largely dependent on the service model and constraints, familial
presenting needs, and the therapist’s theoretical stance.
How the intervention might work
Family therapy for ASD can be hypothesised to work in several
ways (Solomon 2012). Individuals with ASD and family members
can be supported to understand and make sense of the diagnosis
(for example, through the use of psychoeducation).Discussion can
be facilitated about preferences for using different terminology to
describe the core symptoms (for example, autism spectrum ‘disor-
der’ or autism spectrum ‘condition’) and the narratives and mean-
ings that arise from this for individuals and the family unit collec-
tively. The impact of core characteristics (for example, engagement
in routines or impairments in socioemotional reciprocity such as a
lack of empathy) can be explored with a view to reducing feelings
of frustration or annoyance. Interventions can encourage discus-
sion about broad factors and familial patterns or responses that
may contribute to difficulties with communication and relation-
ships or challenging behaviour, and support the identification of
strategies to promote cohesion within the system. Family therapy
can also encourage open dialogue between carers (for example,
about potential guilt or feelings of stress or worry), and in turn,
strategies can be developed to enhance marital relationships, re-
silience and coping, and positive parental mental health. Family
therapy also provides a supportive therapeutic space for siblings
to explore their concerns or unanswered questions (for example,
2Family therapy for autism spectrum disorders (Protocol)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
about heredity factors or their current and potential prospective
role as a carer).
Why it is important to do this review
ASD are common, lifelong disorders characterised by overt and
subtle qualitative impairments in communication, social interac-
tion and relatedness, and preferences for engaging in restricted in-
terests and repetitive behaviours (WHO 1992). Difficulties with
tolerating uncertainty, ambiguity, and change within and beyond
the immediate environment are additional hallmark characteris-
tics (APA 2013). Core ASD symptoms can impact significantly on
daily social and occupational functioning during childhood and
adulthood. Individuals with ASD may find it difficult to initiate
and sustain interactions with others despite the desire for relation-
ships (and increased social opportunities). Also, symptoms of ASD
typically impact others in the family (Hoefman 2014). Parents
(carers) and siblings often must accommodate restricted interests
and adherence to seemingly non-functional routines. Inherent dif-
ficulties with communication and interaction can adversely affect
relationships with, and between, family members. The need to
provide intensive and ongoing support to individuals with ASD
can incur stress, anxiety, and depression in carers, as well as poor
perceived parental efficacy and coping (Karst 2012).
There is no cure for ASD per se, and the heterogeneity of the
disorder negates the use of monotherapy. Instead, the more par-
simonious approach is to develop combinations of interventions
that 1) reduce or ameliorate the effect and impact of core ASD
symptoms, and 2) support individuals and others around them to
enhance their repertoire of skills (Smith 2014; Woodman 2015).
Further, interventions are needed across the lifespan to address the
needs of children as well as adults with ASD. There is promis-
ing evidence for the use of psychological interventions for indi-
viduals with ASD, such as behavioural and cognitive-behavioural
(Lang 2010; Spain 2015a; Sukhodolsky 2013), social cognition
(Fletcher-Watson 2014), and skills-based interventions (Reichow
2013; Spain 2015b), but a limitation to these approaches is that
they do not explicitly address relationship and communication is-
sues between family members, nor do they seek to enhance famil-
ial coping strategies or resilience factors. Similarly, a recent review
has highlighted the potential effectiveness of parent training for
ASD (Oono 2013), but this approach encourages parents to take
on a more facilitative role, rather than specifically targeting their
(potential) concurrent needs and the bi-directional relationship
between individuals. Conversely, family therapy is amore inclusive
intervention and has been found to be effective for different clini-
cal populations (Carr 2009). Whether the structure or content of
family therapy for individuals with ASD requires adaptation (as is
the case for other psychological therapies), for example to accom-
modate the impact of inherent impairments, is not wholly clear.
Undertaking a systematic review of the empirical data is important
in order to:
1. ascertain the potential effectiveness and acceptability of
formal family therapy work for individuals with ASD;
2. establish whether there are integral features of these
approaches that are associated with improved outcomes; and
3. consider how best interventions can be tailored to the
specific lifelong needs of this clinical population and their family
members.
O B J E C T I V E S
To evaluate the clinical effectiveness and acceptability of family
therapy as a treatment to enhance communication or coping for
individuals with ASD and their family members. If possible, we
will also seek to establish the economic costs associated with family
therapy for this clinical population.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) and quasi-randomised con-
trolled trials (q-RCT) (in which participants are allocated by alter-
nate allocation, for example, according to days of the week). We
will exclude cross-over trials due to the issue of carry-over.
Types of participants
Families which have at least one person -- child or adolescent (aged
17 years and under) or adult (aged 18 years and over) -- diagnosed
with an ASD.
We will define autistic spectrum disorder according to clinical cri-
teria of either the International Classification of Diseases, WHO
1992, or the Diagnostic and Statistical Manual for Mental Disor-
ders, APA 2013, and ideally (but not necessarily) diagnosed using
standardised methods of assessment (for example, the Autism Di-
agnostic Interview-Revised, Lord 1994, or the Autism Diagnostic
Observation Schedule, Lord 2000).
We will define family members as individuals from multigenera-
tions (parents, grandparents, siblings, children, or spouses), who
are either biologically related to the individual with ASD, or re-
lated through marriage or cohabitation. We will also include non-
professional carers (for example, individuals who provide foster or
respite care) and significant others, such as friends.
We will include studies that describe interventions delivered to
participants residing in the same dwelling, or interventions that
are offered to family members who live separately.
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Wewill not exclude studies where participants have a comorbidity
or are receiving other treatments concurrently to the family ther-
apy, although we will endeavour to clarify this level of detail from
reports or by contacting trial authors.
Types of interventions
Family therapy
We will include family therapy interventions delivered by at least
one suitably qualified clinician, which are derived from systemic
theories, and specifically focus on understanding, enhancing, and
improving aspects of relationships between individuals with ASD
and at least one family member; or between two or more members
of the family of an individual with ASD (for example, parents, or
parents and siblings). We will include the following modalities of
family therapy: systemic therapy; structural family therapy; strate-
gic family therapy; Milan approaches; solution-focused therapy;
narrative therapy; and behavioural family therapy. The interven-
tion can be offered either face-to-face or via web-based real-time
sessions. We will exclude studies that describe pure bibliotherapy,
psychoeducation, or parent training techniques. There is no stip-
ulation regarding the number or duration of sessions delivered.
Control condition
We will include four main types of comparator interventions:
1. no treatment;
2. provision of standard clinical care (i.e. treatment as usual);
3. a wait-list control (e.g. a delayed-start intervention); and
4. an active comparator (e.g. an alternative psychological
intervention such as applied behavioural analysis or cognitive
behavioural therapy).
Types of outcome measures
We have identified primary and secondary outcomes for individ-
uals with ASD and family members. We will include outcome
measures that generate either dichotomous or continuous data. To
be eligible for inclusion, outcome measures will need to be stan-
dardised and validated. While measures may not necessarily have
been specifically validated for use with the ASD population, many
intervention studies that include participants with ASD utilise
measures (for example, self report questionnaires) that have been
validated in non-ASD samples (Lang 2010; Reichow 2013; Spain
2015a; Spain 2015b). We will describe the psychometric proper-
ties of outcome measures where possible, and highlight whether
there are indicative normative thresholds (that is cut-off scores)
for ASD samples.
Outcome measures can be completed by individuals with ASD,
family members, or via objective (clinician-administered) instru-
ments. We will include outcome measures that have been com-
pleted at different time points, including postintervention or at
follow-up; and those outcomes that relate to short-term changes
(such as attributions about coping or satisfaction with the inter-
vention), and longer-term outcomes (such as direct and indirect
costs).
Primary outcomes
1. Quality or quantity of social interaction and
communication (e.g. Social Responsiveness Scale by Constantino
2003; Autism Diagnostic Observation Schedule by Lord 2000).
2. Mental health morbidity, including stress, anxiety or
depression (e.g. Hospital Anxiety and Depression Scale by
Zigmond 1983).
3. Quality of life (e.g. EQ-5D by Szenda 2007), including
quality of relationships with family members (e.g. Family
Questionnaire by Wiedemann 2002).
4. Adverse effects or events (e.g. increased mental health
morbidities, as measured by the Hospital Anxiety and
Depression Scale; or an increase in challenging behaviour).
Secondary outcomes
1. Confidence in or attributions about coping (e.g.
Attributional Style Questionnaire by Seligman 1984).
2. Satisfaction with treatment (e.g. Client Satisfaction
Questionnaire by Attkisson 1982).
3. Drop out from treatment.
4. Health economic outcomes, including direct costs (e.g.
treatment costs) and indirect costs (e.g. use of clinical services or
work absence due to stress).
Search methods for identification of studies
We will use a search strategy that combines two concepts: the
condition (ASD) AND intervention (family therapy).We will not
limit the search by language, date, or publication status, and we
will seek translation of documents where necessary.
Electronic searches
We will search the following databases.
1. Cochrane Central Register of Controlled Trials
(CENTRAL), part of the Cochrane Library, current issue (and
which includes the specialised register of the Cochrane
Developmental, Psychosocial and Learning Problems Group).
2. Cochrane Database of Systematic Reviews, part of the
Cochrane Library, current issue.
3. Ovid MEDLINE, 1946 to current.
4. Embase (Ovid), 1980 to current.
5. CINAHLPlus (EBSCOhost), 1937 to current.
6. PsycINFO (Ovid), 1806 to current.
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7. Education Resource Information Center (ERIC)
(EBSCOhost), 1966 to current.
8. Sociological Abstracts (ProQuest), 1952 to current.
9. Dissertation Abstracts International (ProQuest).
10. UK Clinical Research Network Study Portfolio (UKCRN) (
public.ukcrn.org.uk/).
11. ClinicalTrials.gov (clinicaltrials.gov).
12. World Health Organisation (WHO) International Clinical
Trials Registry Platform (apps.who.int/trialsearch/default.asp).
13. AutismData (autism.org.uk/autismdata).
We will use the strategy for OvidMEDLINE, shown in Appendix
1, and modify it as appropriate for other databases.
Searching other resources
We will undertake additional searches as follows: 1) we will hand-
search the reference lists of included studies and seminal texts
cited in the protocol; and 2) we will contact experts, including
researchers who have undertaken studies in the field, to ask if they
know of any studies not already identified by the searches.
Data collection and analysis
Selection of studies
Selection of studies will involve several steps. We will initially im-
port all citations retrieved from the searches into EndNote (an
electronic programme used to manage references, EndNote X7).
After removing duplicates, DS and JS will independently screen
the list of titles and abstracts for relevance. DS and JS will obtain
and inspect full reports of any studies that appear relevant, or for
which more information is needed, and then independently assess
each text for eligibility based on the above inclusion criteria. To
enhance reliability, EP will independently review a random 25%
of the total sample of all abstracts obtained, and a random 25%
of all full-text reports retrieved. If disputes arise, such as regarding
the relevance of titles, abstracts, or full reports, we will contact
report authors to provide clarification, or FH will provide further
consultation, or both. With as much as possible information ob-
tained from the aforementioned sources, any disputes will be re-
solved through discussion by the review authors, until consensus
is reached.
Data extraction and management
DS and JS will independently extract data. To enhance rigour, EP
will also independently extract data for a random 25% of studies.
Wewill extract data onto standardised forms usingMicrosoft Excel
before entering the relevant data into Review Manager software
(RevMan 2014).
The data extraction form will include subheadings relating to the
following areas.
1. Study methods (including methods of randomisation,
allocation concealment, and blinding of research personnel or
participants).
2. Ethical approval (provision of informed consent or assent).
3. Referral route (method through which individuals are
referred/present for family therapy).
4. Participant demographics and clinical diagnoses (including
ASD and comorbid diagnoses).
5. Instruments used to diagnose ASD (including clinician-
administered assessments with either participants or informants).
6. Active and comparator interventions (modality, content,
and duration of the active and comparator interventions).
7. Outcome measurements (for individuals with ASD and
their family members; and health outcome data if cited).
8. Results (including descriptive and inferential statistical
data, as well as study results).
9. Adverse events (e.g. whether there has been an increase in
mental health morbidities).
10. Treatment fidelity (e.g. whether a manualised treatment
approach was used, if treatment sessions were independently
reviewed for adherence to the theoretical model, and the
frequency and nature of clinical supervision for trial therapists).
We will attempt to separate the outcomes and results between sites
for any multicentre studies. In the event that data described appear
ambiguous for any of the reports, we will contact the authors for
clarification. If we are unable to liaise with report authors, we will
document this within the review, and the review team will discuss
the discrepancies.
For any non-English language studies, we will endeavour to ar-
range for report translation.
Assessment of risk of bias in included studies
DS and JS will independently assess the risk of bias of all included
studies across six domains: random sequence generation; alloca-
tion concealment; blinding (of participants, trial staff, and com-
pletion of outcome assessments); incomplete outcome data; selec-
tive outcome reporting; and any other potential sources of bias.
For each included study, we will assign each of these domains one
of three ratings: high risk of bias; low risk of bias; or unclear risk of
bias. We have detailed criteria for rating various domains of bias
below, with examples drawn from Chapter 8.5 of the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
Random sequence generation
1. High risk of bias: a non-random method is used to generate
the sequence, such as allocation by alternate days or geographical
location of entry to the trial.
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2. Low risk of bias: random methods (e.g. random number
table or computer random number generator) are used to
generate the sequence to produce comparable groups.
3. Unclear risk of bias: no or insufficient information is
provided on the methods used to generate the sequence to
permit a judgement of high or low risk of bias.
Allocation concealment
1. High risk of bias: participants and researchers may have
been able to foresee assignment to intervention groups due to
insufficient measures used to conceal allocation (such as open
random allocation schedule, unsealed or non-opaque envelopes).
2. Low risk of bias: adequate methods are used to conceal the
allocation (e.g. opaque envelope procedure, central allocation or
by independent personnel outside of the research team) so that
participants and researchers are unable to foresee or influence the
assignment of intervention groups.
3. Unclear risk of bias: no or insufficient detail is provided on
methods used to conceal the allocation sequence to permit a
judgement of high or low risk of bias.
Blinding of participants and research personnel
1. High risk of bias: neither participants nor research
personnel are blinded to the treatment group allocation or study
hypotheses, and outcomes are likely to be influenced by such
lack of blinding; or blinding is attempted and subsequently
broken; or some participants and personnel are blinded while
others are not blinded, which may introduce bias.
2. Low risk of bias: effective measures (e.g. placebo or sham
therapy sessions) are used to blind study participants and
research personnel from knowing intervention group allocation
and study hypotheses; or when blinding is not possible, study
authors are able to justify that the outcome is unlikely to be
influenced by the lack of blinding.
3. Unclear risk of bias: either the study did not address this
outcome or insufficient details are provided on methods of
blinding to permit a judgement of low or high risk of bias.
Blinding of outcome assessment
1. High risk of bias: outcome assessors are not blinded to
treatment allocation of the study participants and the study
hypothesis, and the outcomes are likely to be influenced by lack
of blinding.
2. Low risk of bias: objective measures (such as biomedical
measures of cortisol levels) that are unlikely to be influenced by
the lack of blinding outcome assessors are used; participants are
unaware of which intervention they have been allocated to; or
participants’ knowledge of which intervention they are receiving
does not mediate their response to subjective outcome measures.
3. Unclear risk of bias: there is a lack of detail on methods of
blinding to permit a judgement of high or low risk of bias.
Incomplete outcome data
1. High risk of bias: reasons for missing data are likely to be
related to the true outcome; missing data are not balanced across
groups; or inappropriate methods are used to impute missing
data.
2. Low risk of bias: no incomplete outcome data for each
main outcome; reasons for missing data are unlikely to be related
to true outcome; missing data are balanced across groups; or
appropriate methods have been used to impute the data.
3. Unclear risk of bias: either the study did not address this
outcome, or there is insufficient detail as regards to the amount,
nature, and handling of incomplete outcome data to permit a
judgement of low or high risk of bias.
Selective reporting
1. High risk of bias: not all prespecified outcomes are
reported; or outcomes are reported using methods not
prespecified and for only a subgroup of the sample; or outcomes
are reported that were not prespecified; or outcomes are reported
incompletely and cannot be included in a meta-analysis.
2. Low risk of bias: all outcomes are reported as prespecified in
published protocol, or the protocol is not available, but there is
convincing text that suggests that all prespecified outcomes have
been reported.
3. Unclear risk of bias: there is insufficient information (e.g.
no protocol available) to permit a judgement of high or low risk
of bias.
Other sources of bias
1. High risk of bias: the study raises other important concerns,
such as bias relating to the study design or claims of fraudulence,
or other sources of bias that are not covered by the above
domains.
2. Low risk of bias: there is no evidence to suggest there are
any other important concerns about bias not addressed in the
domains stated above.
3. Unclear risk of bias: there may be an additional risk of bias,
but there is insufficient information to fully assess this risk, or it
is unclear that the risk would introduce bias in the study results.
We will obtain a third opinion from EP, MF, or FH should there
be disagreement about risk assessment or a lack of consensus about
any of the individual domains per study or in terms of the overall
appraisal of the trial.Wewill also attempt to contact report authors
to provide clarification about aspects of the trial, as needed.
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’Summary of findings’ table
We will import data from Review Manager, RevMan 2014, into
GRADEprofiler, GRADEpro GDT, and use this software to cre-
ate ’Summary of findings’ tables. These tables will provide out-
come-specific information concerning the overall quality of the
body of evidence from the studies included in the comparison, the
magnitude of effect of the interventions examined, and the sum
of available data on outcomes rated as relevant to patient care and
decision making.
We will employ the Grades of Recommendation, Assessment, De-
velopment and Evaluation (GRADE) approach to assess the qual-
ity of evidence (Schünemann 2011), using the following ratings:
high quality (RCTs or q-RCTs with a very low risk of bias), mod-
erate quality (RCTs or q-RCTs with some evidence of risk of bias
such as inadequate allocation concealment), low and very lowqual-
ity (RCTs or q-RCTs that have significant threats to internal study
validity such as failure to adequately randomise participants, lack
of blinding of outcome assessors, or selective outcome reporting)
(Higgins 2011, Table 12.2.a).
We will include the following outcomes in the ’Summary of find-
ings’ table.
1. Quality or quantity of social interaction or communication.
2. Mental health morbidity, including stress, anxiety, or
depression.
3. Quality of life.
4. Confidence in or attributions about coping.
5. Adverse effects or events.
Measures of treatment effect
Dichotomous data
For dichotomous outcomes, such as the presence or absence of
challenging behaviour(s), wewill use theMantel-Haenszel method
for computing the pooled risk ratio (RR) (Mantel 1959). We will
use the RR in meta-analyses, rather than the odds ratio (OR),
because theOR can be susceptible to misinterpretation, which can
lead to overestimationof the benefits andharms of the intervention
(Higgins 2011, Section 9.4.4.4). We will report the RR with 95%
confidence intervals (CIs).
Continuous data
Where different measures are used, we will calculate the standard-
ised mean difference and 95% CI. We will calculate the mean dif-
ference and 95% CI where all outcomes are measured using the
same scale in the same way.
Unit of analysis issues
Cluster trials
In cluster trials, the independence of individuals cannot be as-
sumed (Higgins 2011). As we are examining the effectiveness of
an intervention for both individuals and family members, we may
identify cluster randomised trials.
If clustering has been incorporated into the analyses of primary
studies, we plan to present these data as if from a non-cluster ran-
domised study, but adjust for the clustering effect.We will contact
study authors formore information if needed. If we identify cluster
trials that have been analysed using incorrect statistical methods
(that is not taking the clustering into account), we will contact
study authors to request individual participant data so that we
may calculate an estimate of the intracluster correlation coefficient
(ICC). If we are unable to obtain this information, we will adjust
sample sizes using an estimate of the ICC from the trial or from
a trial of a similar population, with advice from a statistician, and
use this to reanalyse the data. In the event that we are unable to
adjust for incorrect statistical methods used by the cluster trials,
and therefore cannot estimate the ICC with any a degree of con-
fidence, we will exclude the trial (Higgins 2011).
We will investigate the robustness of our results by conducting
sensitivity analyses, for example, to explore the impact of different
types of cluster randomisation units (such as families, health prac-
titioners) (Higgins 2011). We will also compare the results with
and without cluster trials that have not been analysed correctly by
the trialists (where the ICC is estimated from other trials for the
adjustment of cluster effect) (see Sensitivity analysis).
Cross-over trials
Due to the issue of carry-over, that is whereby the effectiveness of
a second intervention may be mediated by the first intervention,
we will exclude cross-over trials.
Multiple comparisons
Where a trial involves more than two treatment (or comparator)
arms,wewill first assesswhich intervention (or comparator) groups
are relevant to our review. We will use data from the arms of
the trial that are relevant to the review objectives, but present
all intervention groups in the ’Characteristics of included studies’
tables, providing a detailed description of why we have selected
particular groups and excluded others. In the event that studies
have more than two intervention groups and a control group that
are relevant to the review, we will split the control group data
proportionately to the other two groups.
Repeated measures
Where a trial reports outcome data obtained at more than one
time point, we will conduct analyses separately for each time point
(for example, postintervention and at follow-up if follow-up is
specified by the trialist).
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Dealing with missing data
We will consider the possible impact of missing data on the results
of the review.
Data may be missing either because (1) they have been insuffi-
ciently or inadequately reported, or (2) due to drop out/attrition.
In the event of insufficient or inadequate reporting, we will first
try to obtain any missing data from the trial authors, including
unreported data (for example, group means and standard devia-
tions (SDs)), details of dropouts, and interventions provided. We
will describe the missing data in the ’Risk of bias’ table.
In either case outlined above, and where we cannot obtain data,
we will conduct analyses using intention-to-treat (ITT) principles.
For dichotomous outcomes (those not deemed to be missing at
random), wewill impute the outcomes for themissing participants
using both the most optimistic (that is assuming participants with
missing data improve) and the most pessimistic (that is assuming
participants with missing data deteriorate) scenarios.
Where data are missing for continuous outcomes (for example,
data pertaining tomeans or SD), we will attempt to calculate them
based on the standard errors, CIs, and t values, according to the
rules described in the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011). If this information is missing, and
we are unable to obtain it from trial authors, we will report it as
missing data in the review.
We will also conduct a sensitivity analysis to compare the results
from the ITT analysis with the imputation and ‘available case’
analysis (see Sensitivity analysis). If these analyses yield similar
results in terms of the effects of treatment, we will present the
results of the available case analyses.
Assessment of heterogeneity
Within each comparison, we will first assess clinical heterogene-
ity (for example, variability in active and comparator interven-
tions, participant characteristics, or outcome measures used) and
methodological heterogeneity (for example, variability in study
design, including differences in the nature of the randomisation
unit and the size of cluster randomised; and risk of bias, which
we will assess according to the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011)).
If there is clinical or methodological heterogeneity, we will extract
and document all of these characteristics onto the data extraction
form and synthesise the results narratively. We will then assess sta-
tistical heterogeneity using the I² and Chi² statistics, and by vi-
sually inspecting the forest plots. If we identify a substantial level
of heterogeneity in trials (for example, the I² is more than 30%
to 60%, the P value is less than 0.10 in the Chi² test for hetero-
geneity, or there is a different direction of the effects), we will con-
duct prespecified subgroup analyses (see Subgroup analysis and
investigation of heterogeneity).
Assessment of reporting biases
We will assess reporting biases, including (multiple) publication,
selective reporting, outcome, and language biases (Higgins 2011,
Table 10.1.a). First, we will try to locate protocols of included
trials. If the protocol is available, we will compare outcomes doc-
umented in the protocol and the published report. If the protocol
is not available, we will compare outcomes listed in the methods
section of the trial report with the reported results. In addition,
we will create funnel plots to investigate the possibility of publi-
cation bias and other small-study effects when there is a sufficient
number of trials (10 or more). While funnel plots may be useful
in investigating reporting biases, there is some concern that tests
for funnel plot asymmetry have limited power to detect small-
study effects, particularly when there are fewer than 10 studies,
or where all studies are of similar sample size (Higgins 2011). In
the event that funnel plots are possible, we will produce them and
seek statistical advice in their interpretation.
Data synthesis
We will conduct random-effects meta-analyses to produce the av-
erage effect size of the intervention across trials. A random-effects
model is considered more appropriate than a fixed-effect model
because the population and setting of trials are likely to be differ-
ent, and therefore the effects are also likely to be different (Higgins
2011).
Subgroup analysis and investigation of heterogeneity
Depending on the sample size and heterogeneity of study popu-
lations, we propose to undertake subgroup analyses as follows:
1. Children and adolescents (aged 17 years and under) versus
adults (aged 18 years and above) with ASD.
2. Individuals with ASD who have a concurrent learning
disability (i.e. intelligence quotient (IQ) below 70) versus
individuals with ASD and no learning disability.
To limit the risk of multiple comparisons, we will conduct sub-
group analyses on primary outcomes only.
Sensitivity analysis
We will undertake sensitivity analyses to evaluate the impact of
excluding trials (or trial data) that are judged to have a high risk
of bias (for example, in terms of the domains of random sequence
generation, allocation concealment, blinding, or outcome report-
ing). We will also undertake sensitivity analyses to assess the po-
tential impact of missing outcome data.
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Appendix 1. Search strategy
1. exp child development disorders, pervasive/
2. Developmental Disabilities/
3. pervasive development$ disorder$.tw.
4. (pervasive adj3 child$).tw.











16. (systemic$ adj3 psychotherap$).tw.
17. (systemic$ adj3 psycho-therap$).tw.
18. (systemic$ adj3 famil$).tw.
19. (famil$ adj3 (intervention$ or therap$ or treat$ or program$)).tw.
20. (famil$ adj3 (psychotherap$ or psychoeducation$ or psycho-education$ or psycho-therap$)).tw.
21. ((marriage or marital or couple$) adj3 therap$).tw.
22. (famil$ adj1 (involv$ or integrat$ or participat$ or focus$)).tw.
23. (psychodynamic or psycho-dynamic).tw.
24. (group$ adj3 psychotherap$).tw.
25. (group$ adj3 psycho therap$).tw.
26. systemic therap$.tw.
27. solution focus$.tw.
28. (narrative adj1 therap$).tw
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29. or/11-28
30. 10 and 29
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DS: Review of proposal; design and preparation of the protocol. Will contribute to: screening of abstracts and studies; data extraction
and quality appraisal of studies; initiating requests for further information from researchers who have undertaken potentially relevant
studies; data analysis; and preparation of the review.
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of studies; data analysis; and preparation of the review.
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of studies; data analysis; and preparation of the review.
MF: Design and preparation of the protocol. Will contribute to: statistical advice and data analysis; and preparation of the review.
TC: Preparation of the protocol. Will contribute to: data analysis and preparation of the review.
DGM: Preparation of the protocol. Will contribute to: data analysis and preparation of the review.
FGH: Preparation of the protocol. Will contribute to: data extraction; statistical advice and data analysis; and preparation of the review.
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